Pharmacyclics Announces Presentations and Published Abstracts on
Xcytrin at The 2007 American Society of Clinical Oncology Annual
Meeting

SUNNYVALE, Calif., May 23, 2007 /PRNewswire-FirstCall/ --
Pharmacyclics, Inc. announced today multiple presentations and a
published abstract regarding Xcytrin(R) (motexafin gadolinium)
Injection, including an oral presentation of Phase 3 SMART (Study
of Neurologic Progression with Motexafin Gadolinium And Radiation
Therapy) trial data. The presentations and publications are part of
the proceedings at the 2007 American Society of Clinical Oncology
Annual Meeting (ASCO) that will be held June 1-5, 2007, at
McCormick Place in Chicago, IL.

Pharmacyclics is developing Xcytrin as an anti-cancer agent with
a novel mechanism of action that is designed to selectively
concentrate in tumors and induce apoptosis (programmed cell death).
Xcytrin is a redox-active drug that has been shown to disrupt
redox-dependent pathways in cells and inhibit oxidative stress
related proteins. Its multifunctional mode of action, including its
magnetic resonance imaging detectability, provides the opportunity
for Xcytrin to be used in a broad range of cancers.

About Pharmacyclics

Pharmacyclics is a pharmaceutical company developing innovative
products to treat cancer and other serious diseases. The company is
leveraging its small-molecule drug development expertise to build a
pipeline in oncology and other diseases based on a wide range of
targets, pathways and mechanisms. Its lead product, Xcytrin(R), has
completed Phase 3 clinical trials and several ongoing Phase 1 and
Phase 2 clinical trials are evaluating Xcytrin, either as a single
agent or in combination with chemotherapy and/or radiation in
multiple cancer types. More information about the company, its
technology, and products can be found at http://www.pharmacyclics.com.
Pharmacyclics(R), Xcytrin(R) and the "pentadentate" logo(R) are
registered trademarks of Pharmacyclics, Inc.